Literature DB >> 8517661

Osteoblastic metastasis in advanced prostate cancer.

M Koutsilieris1.   

Abstract

Metastatic prostate cancer is unique in its ability to induce the osteoblastic reaction in skeleton. This phenomenon is probably the result of complex paracrine/autocrine cell interaction between prostate cancer cells and bone cells at the metastatic sites. Recently the use of various in vivo and in vitro systems made possible the confirmation of certain cellular interactions that may participate in this process. The role of IGFs/GFBPs, urokinase-type plasminogen activator (uPA), as well as of TGF beta 1 and glucocorticoids is discussed in this review.

Entities:  

Mesh：

Year:  1993        PMID： 8517661

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  19 in total

1.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.

Authors:  P Burfeind; C L Chernicky; F Rininsland; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Notch and the regulation of osteoclast differentiation and function.

Authors:  Jungeun Yu; Ernesto Canalis
Journal:  Bone       Date:  2020-06-08       Impact factor: 4.398

3.  Three-dimensional trabecular bone architecture of the lumbar spine in bone metastasis from prostate cancer: comparison with degenerative sclerosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Skeletal Radiol       Date:  2004-11-16       Impact factor: 2.199

4.  Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton.

Authors:  C Reyes-Moreno; M Koutsilieris
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

Review 5.  Notch Signaling and the Skeleton.

Authors:  Stefano Zanotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2016-04-13       Impact factor: 19.871

6.  Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Authors:  Khalid A Mohamedali; Zhi Gang Li; Michael W Starbuck; Xinhai Wan; Jun Yang; Sehoon Kim; Wendy Zhang; Michael G Rosenblum; Nora M Navone
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

7.  Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer.

Authors:  Eunsohl Lee; Jingcheng Wang; Younghun Jung; Frank C Cackowski; Russell S Taichman
Journal:  J Cell Biochem       Date:  2018-01-09       Impact factor: 4.429

8.  Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow.

Authors:  Eunsohl Lee; Ann M Decker; Frank C Cackowski; Lulia A Kana; Kenji Yumoto; Younghun Jung; Jingcheng Wang; Laura Buttitta; Todd M Morgan; Russell S Taichman
Journal:  J Cell Biochem       Date:  2016-09-26       Impact factor: 4.429

Review 9.  Bone metabolism and new targets for intervention.

Authors:  Bulent Akduman; E David Crawford
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

Review 10.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.